BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma

Cancer Medicine

Volumn 4, Issue 6, 2015, Pages 791-799

  Henke, Lauren E ^a   Pfeifer, John D ^a   Ma, Changquing ^a   Perkins, Stephanie M ^a   Dewees, Todd ^a   El Mofty, Samir ^a   Moley, Jeffrey F ^a   Nussenbaum, Brian ^a   Haughey, Bruce H ^a   Baranski, Thomas J ^a   Schwarz, Julie K ^a   Grigsby, Perry W ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRAF mutation; BRAF mutation survival; BRAF V600; Papillary thyroid carcinoma; Thyroidectomy

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAF GENE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CERVICAL LYMPH NODE; CHILD; DISEASE SPECIFIC SURVIVAL; FEMALE; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; RISK FACTOR; THYROID CARCINOMA; TUMOR INVASION; UNITED STATES; VERY ELDERLY; CARCINOMA; EPIDEMIOLOGY; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MUTATION; PRESCHOOL CHILD; PROGNOSIS; THYROID NEOPLASMS; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; RISK FACTORS; THYROID NEOPLASMS; UNITED STATES; YOUNG ADULT;

EID: 85006217690     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.417     Document Type: Article

References (40)

1. Davies, L., and H. G. Welch . 2006. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167.
2. Hundahl, S. A., I. D. Fleming, A. M. Fremgen, and H. R. Menck . 1998. A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83:2638-2648.
3. Chen, A. Y., A. Jemal, and E. M. Ward . 2009. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 115:3801-3807.
4. Sipos, J. A., and E. L. Mazzaferri . 2010. Thyroid cancer epidemiology and prognostic variables. Clin. Oncol. (R. Coll. Radiol.) 22:395-404.
5. Enewold, L., K. Zhu, E. Ron, A. J. Marrogi, A. Stojadinovic, G. E. Peoples, et al. 2009. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol. Biomarkers Prev. 18:784-791.
6. Yip, L., M. N. Nikiforova, S. E. Carty, J. H. Yim, M. T. Stang, M. J. Tublin, et al. 2009. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery 146:1215-1223.
7. Xing, M. 2005. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 12:245-262.
8. Fagin, J. A., and N. Mitsiades . 2008. Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract. Res. Clin. Endocrinol. Metabol. 22:955-969.
9. Elisei, R., C. Ugolini, D. Viola, C. Lupi, A. Biagini, R. Giannini, et al. 2008. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J. Clin. Endocrinol. Metab. 93:3943-3949.
10. Halait, H., K. Demartin, S. Shah, S. Soviero, R. Langland, S. Cheng, et al. 2012. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diagn. Mol. Pathol. 21:1-8.
11. Ihle, M. A., J. Fassunke, K. Konig, I. Grunewald, M. Schlaak, N. Kreuzberg, et al. 2014. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer 14:13.
12. Rubinstein, J. C., M. Sznol, A. C. Pavlick, S. Ariyan, E. Cheng, A. Bacchiocchi, et al. 2010. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J. Transl. Med. 8:67.
13. Lupi, C., R. Giannini, C. Ugolini, A. Proietti, P. Berti, M. Minuto, et al. 2007. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 92:4085-4090.
14. Kebebew, E., J. Weng, J. Bauer, G. Ranvier, O. H. Clark, Q. Y. Duh, et al. 2007. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann. Surg. 246:466-470, discussion 70-1.
15. Lin, K. L., O. C. Wang, X. H. Zhang, X. X. Dai, X. Q. Hu, and J. M. Qu . 2010. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann. Surg. Oncol. 17:3294-3300.
16. Zeiger, M. A., and E. B. Schneider . 2013. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann. Surg. Oncol. 20:3-4.
17. Elisei, R., D. Viola, L. Torregrossa, R. Giannini, C. Romei, C. Ugolini, et al. 2012. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J. Clin. Endocrinol. Metab. 97:4390-4398.
18. Xing, M., A. S. Alzahrani, K. A. Carson, D. Viola, R. Elisei, B. Bendlova, et al. 2013. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309:1493-1501.
19. Xing, M., W. H. Westra, R. P. Tufano, Y. Cohen, E. Rosenbaum, K. J. Rhoden, et al. 2005. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 90:6373-6379.
20. Fugazzola, L., D. Mannavola, V. Cirello, G. Vannucchi, M. Muzza, L. Vicentini, et al. 2004. BRAF mutations in an Italian cohort of thyroid cancers. Clin. Endocrinol. (Oxf). 61:239-243.
21. Fugazzola, L., E. Puxeddu, N. Avenia, C. Romei, V. Cirello, A. Cavaliere, et al. 2006. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr. Relat. Cancer 13:455-464.
22. Ito, Y., H. Yoshida, R. Maruo, S. Morita, T. Takano, M. Hirokawa, et al. 2009. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr. J. 56:89-97.
23. Brzezianska, E., D. Pastuszak-Lewandoska, K. Wojciechowska, M. Migdalska-Sek, A. Cyniak-Magierska, E. Nawrot, et al. 2007. Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population. Neuro. Endocrinol. Lett. 28:351-359.
24. Gouveia, C., N. T. Can, A. Bostrom, J. P. Grenert, A. van Zante, and L. A. Orloff . 2013. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. JAMA otolaryngology- Head Neck Surg. 139:1164-1170.
25. Tufano, R. P., G. V. Teixeira, J. Bishop, K. A. Carson, and M. Xing . 2012. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore) 91:274-286.
26. Ricarte-Filho, J., I. Ganly, M. Rivera, N. Katabi, W. Fu, A. Shaha, et al. 2012. Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension. Thyroid 22:575-584.
27. DeLellis, R.; IARC, WHO, Pathology IAo, Cancer IAftSoL. 2004. Pathology & genetics: tumours of endocrine organs. In R. A. DeLellis, and P. U. Heitz, eds. IARC Press, Lyon, France.
28. Furlan, J. C., Y. C. Bedard, and I. B. Rosen . 2004. Role of fine-needle aspiration biopsy and frozen section in the management of papillary thyroid carcinoma subtypes. World J. Surg. 28:880-885.
29. Kurian, E. M., M. Dawlett, J. Wang, Y. Gong, and M. Guo . 2012. The triage efficacy of fine needle aspiration biopsy for follicular variant of papillary thyroid carcinoma using the Bethesda reporting guidelines. Diagn. Cytopathol. 40(Suppl. 1):E69-E73.
30. Zatelli, M. C., G. Trasforini, S. Leoni, G. Frigato, M. Buratto, F. Tagliati, et al. 2009. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur. J. Endocrinol. 161:467-473.
31. Lee, X., M. Gao, Y. Ji, Y. Yu, Y. Feng, Y. Li, et al. 2009. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann. Surg. Oncol. 16:240-245.
32. Oler, G., K. N. Ebina, P. Jr Michaluart, E. T. Kimura, and J. Cerutti . 2005. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clin. Endocrinol. (Oxf) 62:509-511.
33. Park, S. Y., Y. J. Park, Y. J. Lee, H. S. Lee, S. H. Choi, G. Choe, et al. 2006. Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. Cancer 107:1831-1838.
34. American Thyroid Association Guidelines Taskforce on Thyroid NDT Cancer; Cooper D. S., Doherty G. M., Haugen B. R., Kloos R. T., Lee S. L., Mandel S. J., et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009 19:1167-1214.
35. Cooper, D. S., G. M. Doherty, B. R. Haugen, R. T. Kloos, S. L. Lee, S. J. Mandel, et al. 2006. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109-142.
36. Kim, S. J., K. E. Lee, J. P. Myong, J. H. Park, Y. K. Jeon, H. S. Min, et al. 2012. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J. Surg. 36:310-317.
37. Kim, T. H., Y. J. Park, J. A. Lim, H. Y. Ahn, E. K. Lee, Y. J. Lee, et al. 2012. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118:1764-1773.
38. Howell, G. M., M. N. Nikiforova, S. E. Carty, M. J. Armstrong, S. P. Hodak, M. T. Stang, et al. 2013. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann. Surg. Oncol. 20:47-52.
39. Ouyang, B., J. A. Knauf, E. P. Smith, L. Zhang, T. Ramsey, N. Yusuff, et al. 2006. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin. Cancer Res. 12:1785-1793.
40. Brose, M. S., C. M. Nutting, B. Jarzab, R. Elisei, S. Siena, L. Bastholt, et al. 2014. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384(9940):319-28. PubMed PMID: 24768112.